Acute myeloid leukemia with 11q23 abnormalities | UniteRare Disease Library

Overview

Also known as:

Acute myeloid leukemia AML AML with 11q23 abnormalities

FDA & Trial Timeline

10 events

Jul 2026Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI) — PHASE2

TrialNOT YET RECRUITING

Feb 2026GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

University of Manchester — PHASE1, PHASE2

TrialNOT YET RECRUITING

Oct 2025Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

University of Washington — NA

TrialRECRUITING

Sep 2025Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Kura Oncology, Inc. — PHASE3

TrialRECRUITING

Sep 2025Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Fred Hutchinson Cancer Center — PHASE1, PHASE2

TrialRECRUITING

Jun 2025CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies

Institute of Hematology & Blood Diseases Hospital, China — PHASE1

TrialRECRUITING

Mar 2025A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

M.D. Anderson Cancer Center — PHASE1

TrialRECRUITING

Feb 2025UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — PHASE1

TrialRECRUITING

Nov 2024Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

Peking University People's Hospital

TrialRECRUITING

Oct 2024The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

Ruijin Hospital

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Acute myeloid leukemia with 11q23 abnormalities.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →

Phase 35 trials

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Active

PI: Richard Aplenc (Children's Oncology Group) · Sites: Birmingham, Alabama; Birmingham, Alabama +218 more · Age: 0–29 yrs

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Phase 3

Active

PI: Dragan Cicic Chief Development Officer, MD (Sellas Life Sciences Group) · Sites: Birmingham, Alabama; Los Angeles, California +71 more · Age: 18–99 yrs

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Phase 3

Active

· Sites: Duarte, California; Los Angeles, California +17 more · Age: 18–65 yrs

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

Phase 3

Actively Recruiting

PI: Xiaojun Huang, Doctor (Peking University People's Hospital) · Sites: Hefei, Anhui; Hefei, Anhui +51 more · Age: 18–99 yrs

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Phase 3

Actively Recruiting

· Sites: Gilbert, Arizona; La Jolla, California +27 more · Age: 18–99 yrs

Phase 26 trials

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Actively Recruiting

PI: Tapan M Kadia (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 50–99 yrs

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

Phase 2

Active

PI: Gabriell Hobbs, MD (Massachusetts General Hospital) · Sites: Boston, Massachusetts; Boston, Massachusetts +4 more · Age: 60–80 yrs

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Phase 2

Active

PI: Rory M Shallis (Yale University Cancer Center LAO) · Sites: Orange, California; New Haven, Connecticut +9 more · Age: 18–99 yrs

Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

Phase 2

Active

· Sites: Alessandria; Ancona +31 more · Age: 60–99 yrs

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

Phase 2

Actively Recruiting

PI: Alice S Mims, MD (Ohio State University Comprehensive Cancer Center) · Sites: Columbus, Ohio · Age: 18–99 yrs

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2

Active

PI: Uday R Popat (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 2–70 yrs

Other6 trials

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

Active

PI: Nishant Dwivedi, MD/PhD (CareDx) · Sites: Brisbane, California; Duarte, California +8 more · Age: 18–99 yrs

The Efficacy of Allo-HSCT in ND HR-CBF-AML

Actively Recruiting

PI: Yang Shen, MD, PhD (Ruijin Hospital, Shanghai, China) · Sites: Shanghai, Shanghai Municipality · Age: 18–65 yrs

Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

Actively Recruiting

· Sites: Beijing, Beijing Municipality; Beijing, Beijing Municipality · Age: 0–18 yrs

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9

Enrolling by Invitation

PI: Anne Roivainen (Turku University Hospital, Turku PET Centre) · Sites: Turku · Age: 18–100 yrs

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

Actively Recruiting

· Sites: Amiens; Angers +26 more · Age: 0–25 yrs

The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia

Actively Recruiting

· Sites: Shanghai, Shanghai Municipality · Age: 18–65 yrs

Specialists

Showing 25 of 71View all specialists →

Soheil Meshinchi, MD

SEATTLE, WA

Specialist

Acute basophilic leukemia Acute megakaryoblastic leukemia Inherited acute myeloid leukemia

PI on 4 active trials

Overview

FDA & Trial Timeline

Treatments

Clinical Trials

Specialists

Treatment Centers

Travel Grants

Community

Latest news about Acute myeloid leukemia with 11q23 abnormalities

Caregiver Resources

Common questions about Acute myeloid leukemia with 11q23 abnormalities